MPM Oncology Impact Management »

Eliem Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Eliem Therapeutics (CLYM) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Eliem Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Eliem Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eliem Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $11M 2.7M 4.00

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Eliem Therapeutics

RA Capital Management
MPM Oncology Impact Management
ADAR1 Capital Management
Vanguard Group
Affinity Asset Advisors
Kynam Capital Management
Dr. Jeffrey R. Jay, M.D.
Sphera Funds Management
Point72 Asset Management
Peapod Lane Capital
Millennium Management
Nan Fung Trinity
Susquehanna International
BlackRock
Renaissance Technologies

View all funds holding Eliem Therapeutics